Search Results - "Plavina, T."

Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial by Bozic, C., Subramanyam, M., Richman, S., Plavina, T., Zhang, A., Ticho, B.

“…Background and purpose Progressive multifocal leukoencephalopathy (PML) is caused by reactivation of JC virus (JCV) infection due to combined host and viral…”
Get full text

Changes to anti-JCV antibody levels in a Swedish national MS cohort by Warnke, Clemens, Ramanujam, Ryan, Plavina, Tatiana, Bergström, Tomas, Goelz, Susan, Subramanyam, Meena, Kockum, Ingrid, Rahbar, Afsar, Kieseier, Bernd C, Holmén, Carolina, Olsson, Tomas, Hillert, Jan, Fogdell-Hahn, Anna

“…Background The anti-JC virus (JCV) antibody status has been introduced to stratify patients with multiple sclerosis (MS) for higher or lower risk of…”
Get full text

Anti-JC Virus Antibody Titer Changes during Natalizumab Treatment in a Swedish MS Cohort (P02.139) by Warnke, C., Subramanyam, M., Bergstrom, T., Goelz, S., Plavina, T., Kockum, I., Rahbar, A., Olsson, T., Hillert, J., Fogdell-Hahn, A.

“…Abstract only…”
Get full text

Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy by Salmen, A., von Ahsen, N., Trampe, A.K., Hoepner, R., Plavina, T., Subramanyam, M., Kuesters, G., Gold, R., Chan, A.

“…Risk assessment for natalizumab-associated progressive multifocal leukoencephalopathy (Nat-PML) comprises the anti-JC virus (JCV) antibody index (AI). The…”
Get full text

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

Get full text

Blood neurofilament light levels segregate treatment effects in multiple sclerosis by Delcoigne, Bénédicte, Manouchehrinia, Ali, Barro, Christian, Benkert, Pascal, Michalak, Zuzanna, Kappos, Ludwig, Leppert, David, Tsai, Jon A., Plavina, Tatiana, Kieseier, Bernd C., Lycke, Jan, Alfredsson, Lars, Kockum, Ingrid, Kuhle, Jens, Olsson, Tomas, Piehl, Fredrik

“…OBJECTIVETo determine factors (including the role of specific disease modulatory treatments [DMTs]) associated with (1) baseline, (2) on-treatment, and (3)…”
Get full text

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort by Olsson, Tomas, Achiron, Anat, Alfredsson, Lars, Berger, Thomas, Brassat, David, Chan, Andrew, Comi, Giancarlo, Eraksoy, Mefkure, Hegen, Harald, Hillert, Jan, Jensen, Poul Erik Hyldgaard, Moiola, Lucia, Myhr, Kjell-Morten, Oturai, Annette, Schippling, Sven, Siva, Aksel, Sorensen, Per Soelberg, Trampe, Anne-Kathrin, Weber, Thomas, Potts, James, Plavina, Tatiana, Paes, Dominic, Subramanyam, Meena, Wiendl, Heinz, Dib, Hussein, Üren, Deniz, Hemmer, Bernhard, Buck, Dorothea

“…JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large,…”
Get full text

Anti-JCV Antibody Prevalence in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: Baseline Results of STRATIFY-2 (S41.002) by Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J., Subramanyam, M., Sandrock, A., Bloomgren, G.

“…Abstract only…”
Get full text

Updated Incidence of Progressive Multifocal Leukoencephalopathy in Natalizumab-Treated Multiple Sclerosis Patients Stratified by Established Risk Factors (S41.001) by Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Natarajan, A., Lee, S., Plavina, T., Scanlon, J., Sandrock, A., Bozic, C.

“…Abstract only…”
Get full text

RESTORE Study: Effects of a 24-Week Natalizumab Treatment Interruption on Immune Parameters and Multiple Sclerosis Magnetic Resonance Imaging Disease Activity (P06.168) by Cree, B., De Seze, J., Fox, R., Gold, R., Hartung, H., Jeffery, D., Kappos, L., Kaufman, M., Montalban, X., Weinstock-Guttman, B., Natarajan, A., Subramanyam, M., Plavina, T., Woodworth, J., Duda, P.

“…Abstract only…”
Get full text

Evaluation of the incidence of anti-JC virus antibodies in a cohort of natalizumab-treated patients by Pepio, A, Taylor, L, Jaros, M, Mocci, S, Taylor, J, Yednock, T, Plavina, T, Gorelik, L, Goelz, S, Subramanyam, M

Get full text

Plasma neurofilament light levels segregate treatment effects: results from the IMSE studies with multiple disease modulatory drugs by Delcoigne, B, Manouchehrinia, A, Barro, C, Michalak, Z, Kappos, L, Leppert, D, Tsai, J, Plavina, T, Kieseier, BC, Alfredsson, L, Kockum, I, Kuhle, J, Olsson, T, Piehl, F

Get full text

International multi-site analytical validation of the Simoa NF-light assay in human serum samples from multiple sclerosis patients by Kuhle, J, Barro, C, Hrusovsky, K, Chang, L, Jeromin, A, Bridel, C, Bar-Or, A, Bittner, S, Bruck, W, Bielekova, B, Chitnis, T, Comi, G, Comabella, M, Arrambide, G, Montalban, X, Datwani, A, Fluck, M, Fox, R, Freedman, M, Furlan, R, Gnanapavan, S, Giovannoni, G, Havari, E, Khalil, M, Leppert, D, Kropshofer, H, Valentin, MA, Oksenberg, J, Piehl, F, Plavina, T, Sormani, MP, Lehmann, S, Thouvenot, E, Ziemssen, T, Zipp, F, Gross, C, Wiendl, H, Kappos, L, Michalak, Z, Blennow, K, Zetterberg, H, Teunissen, C, Wilson, D

Get full text

Anti-JCV antibody titre changes during natalizumab treatment in a Swedish MS cohort by Warnke, C, Subramanyam, M, Plavina, T, Olsson, T, Kockum, I, Hillert, J, Goelz, S, Fogdell-Hahn, A

Get full text

Prevalence of anti-JCV antibodies in a multi-national cohort of multiple sclerosis patients by Olsson, T, Achiron, A, Alfredsson, L, Chan, A, Comi, G, Hillert, J, Moiola, L, Oturai, A, Sorensen, P, Potts, J, Hotermans, C, Plavina, T, Paes, D, Subramanyam, M

Get full text